Nasdaq btai.

BioXcel Therapeutics Inc. Follow. Share. $3.93. After Hours: $3.90. (0.76%) -0.030. Closed: Nov 24, 4:39:38 PM GMT-5 · USD · NASDAQ · Disclaimer. search Compare to.NEW HAVEN, Conn., March 09, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ...NEW HAVEN, Conn., March 01, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...Nov 26, 2023 · Allogene Therapeutics (NASDAQ:) is a clinical-stage biotech firm specializing in developing allogeneic T cell cancer treatment therapies. Around 67.4% of ALLO’s share count consists of publicly ...

Isaac Mitchell. November 25, 2023. Technologies. BioXcel Therapeutics Inc (NASDAQ:BTAI)’s traded shares stood at 0.4 million during the last session, with the company’s beta value hitting 0.78. At the close of trading, the stock’s price was $4.00, to imply an increase of 4.44% or $0.17 in intraday trading. The BTAI share’s 52-week high ...

You can also contact BioXcel Therapeutics, Inc. at 1-833-201-1088 or [email protected]. Please see full Prescribing Information . BioXcel Therapeutics, Inc., is a biopharmaceutical ...Biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience.

Find the latest on option chains for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.BioXcel Therapeutics, Inc. (NASDAQ:BTAI) issued its earnings results on Monday, August, 14th. The company reported ($1.83) earnings per share for the quarter, …NEW HAVEN, Conn., Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology.

Apr 28, 2023 · 586,279. 6.770742. Back to BTAI Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end ...

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) to host virtual Neuroscience R&D Day to discuss BXCL502, a potential treatment for chronic agitation in dementia, along with other emerging pipeline candidates. Dr. Jeffrey Cummings and Dr. Sandra Comer to discuss agitation relief in Alzheimer’s disease and BXCL501 as a potential treatment for opioid …

BioXcel Therapeutics, Inc. Common Stock (BTAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Nov 14, 2023 · On November 14, 2023, BioXcel Therapeutics Inc ( NASDAQ:BTAI) released its 8-K filing, announcing strategic advancements and financial results for the third quarter ended September 30, 2023. The ... Jun 29, 2023 · BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today ... BioXcel Therapeutics Inc Follow Share $3.93 After Hours: $3.90 (0.76%) -0.030 Closed: Nov 24, 4:39:38 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare to Ardelyx Inc …Find the latest Institutional Holdings data for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.

Find the latest on option chains for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.NEW HAVEN, Conn., March 15, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call Transcript November 14, 2023 BioXcel Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.72 EPS, expectations ... NEW HAVEN, Conn., Nov. 09, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...AI. BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.Fintel reports that on July 3, 2023, HC Wainwright & Co. maintained coverage of BioXcel Therapeutics (NASDAQ:BTAI) with a Buy recommendation. Analyst Price Forecast Suggests 586.04% Upside. As of ...

BioXcel Therapeutics ( BTAI 2.61%) stock is plummeting Monday. The clinical-stage biotech specialist's share price is down 44.6% as of 11:15 a.m. ET, according to data from S&P Global Market ...Find the latest Institutional Holdings data for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.

View the latest BioXcel Therapeutics Inc. (BTAI) stock price, news, historical charts, analyst ratings and financial information from WSJ. BTAI stock is down 57.2% as of Thursday morning. That comes as some 3.2 million shares change hands, as compared to its daily average trading volume of about 549,000 shares. Investors seeking out ...Over the past 3 months, 10 analysts have published their opinion on BioXcel Therapeutics (NASDAQ:BTAI) stock. These analysts are typically employed by large Wall Street banks and tasked with ...NEW HAVEN, Conn., Feb. 13, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...Live webcast to be held on June 25th from 12:00 PM ET – 1:30 PM ET... NEW HAVEN, Conn., June 18, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI ...Back to BTAI Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.BTAI BioXcel Therapeutics Inc Stock - Share Price, Short Interest, Short Squeeze, Borrow Rates (NASDAQ) ... CT 06511 | www.bioxceltherapeutics.com September 2022 AI-Driven Drug Development in Neuroscience and Immuno-oncology NASDAQ: BTAI This presentation includes "forward-looking state 2022-09-12 - 2 viewsInvestigation Alert BAX, DHR, BTAI, and IBRX: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below GlobeNewswire Sep 26, 2023 4:27pm Trading InformationBTAI's current price target is $23.88. Learn why top analysts are making this stock forecast for BioXcel Therapeutics at MarketBeat.

Find the latest Earnings Report Date for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.

Shares of BioXcel Therapeutics ( BTAI -1.71%) were down more than 19% early Thursday afternoon after the biotech company released the first part of a phase 3 trial for the therapy BXCL501 ...

NEW HAVEN, Conn., Sept. 09, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel” or the “Company”), a clinical-stage biopharmaceutical company utilizing artificial ...NEW HAVEN, Conn., April 29, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...NEW HAVEN, Conn., Dec. 07, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...Nov 30, 2023 · The public float for BTAI is 20.22M, and currently, short sellers hold a 25.11% ratio of that floaft. The average trading volume of BTAI on November 30, 2023 was 3.17M shares. BTAI) stock’s latest price update. BioXcel Therapeutics Inc (NASDAQ: BTAI)’s stock price has dropped by -0.26 in relation to previous closing price of 3.91. 27 Oct 2023 ... Fintel reports that on October 26, 2023, HC Wainwright & Co. reiterated coverage of BioXcel Therapeutics (NASDAQ:BTAI) with a Buy ...NEW HAVEN, Conn., Oct. 18, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ...NEW YORK, Aug. 27, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...BioXcel Therapeutics (NASDAQ:BTAI) stock is rocketing higher on Wednesday after the biopharmaceutical company announced results from an audit of its Tranquility II clinical trial.. According to a ...BTAI's recent financials show a net loss of $53.5MM for 2Q23, with a cash reserve expected to last until mid-2024. Strategic financing negotiations are underway. We maintain a hold rating on ...

BioXcel Therapeutics, Inc. Common Stock (BTAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Which BioXcel Therapeutics insiders have been selling company stock? The following insiders have sold BTAI shares in the last 24 months: Frank Yocca ($1,519,394.65), Javier Rodriguez ($48,766.20), Krishnan Nandabalan ($2,029,310.26), Richard I Steinhart ($176,488.00), and Vimal Mehta ($2,029,075.00).NEW HAVEN, Conn., May 11, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...NEW HAVEN, Conn., Jan. 05, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...Instagram:https://instagram. et stock dividend historyarabsstockdocusign stoclfacet financial reviews According to NASDAQ, as of May 2014, the highest NASDAQ closing ever was achieved on March 9, 2000, when the market closed at a record 5046.86. USA Today reports that the highest closing achieved by NASDAQ since was a 4007.09 closing on Nov...NEW YORK, Aug. 27, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that... scty stock priceycs stock BTAI support price is $3.53 and resistance is $4.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BTAI stock will trade within this expected range on the day. View a ...NEW HAVEN, Conn., May 12, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ... financial advisor orange ca BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning ...BioXcel Therapeutics to host conference call today at 8:00 a.m. ET. NEW HAVEN, Conn., June 29, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company ...